Intellia Therapeutics

Intellia Therapeutics is a genome editing company developing curative gene editing therapies. It has the potential to positively transform the lives of people suffering from severe and life-threatening diseases. Intellia has exclusive access to one of the most comprehensive intellectual property platforms for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline in clinical development, including both ex vivo and in vivo approaches.